Percentage of cytogenetic abnormalities in Medical Research Council trials AML10 and AML11
| Abnormality . | All patients (n = 2677), no. (%) . | de novo (n = 2310), % . | Secondary (n = 367), % . | 0-14 years (n = 340), % . | 15-34 years (n = 461), % . | 35-54 years (n = 783), % . | 55+ years (n = 1093), % . |
|---|---|---|---|---|---|---|---|
| None | 1187 (44) | 45 | 38 | 27 | 38 | 51 | 48 |
| +8 | 257 (10) | 9 | 135-150 | 14 | 10 | 7 | 105-151 |
| Complex | 241 (9) | 8 | 155-151 | 6 | 6 | 6 | 135-150 |
| t(15;17) | 241 (9) | 10 | 25-151 | 9 | 19 | 10 | 45-151 |
| −7 | 148 (6) | 4 | 125-151 | 4 | 3 | 4 | 8 |
| t(8;21) | 145 (5) | 6 | 2 | 12 | 6 | 7 | 25-151 |
| del(5q) | 108 (4) | 3 | 85-150 | 1 | 1 | 2 | 75-151 |
| −5 | 81 (3) | 3 | 55-150 | 1 | 2 | 2 | 55-151 |
| del(7q) | 80 (3) | 3 | 5 | 2 | 2 | 2 | 4 |
| 11q23 | 72 (3) | 3 | 1 | 8 | 5 | 2 | 15-151 |
| +21 | 71 (3) | 3 | 4 | 6 | 3 | 1 | 25-151 |
| inv(16) | 69 (3) | 3 | 1 | 5 | 6 | 2 | 15-151 |
| abn(3q) | 67 (3) | 2 | 45-150 | 2 | 3 | 2 | 3 |
| del(9q) | 49 (2) | 2 | 2 | 4 | 1 | 1 | 2 |
| +22 | 37 (1) | 1 | 2 | 1 | 2 | 1 | 1 |
| t(9;22) | 18 (1) | 1 | 1 | 1 | 0 | 1 | <1 |
| t(6;9) | 15 (1) | 1 | 0 | 1 | 1 | 1 | <15-151 |
| Other structural | 634 (24) | 22 | 375-151 | 29 | 18 | 20 | 275-150 |
| Other numerical | 560 (21) | 20 | 265-150 | 23 | 18 | 15 | 26 |
| Abnormality . | All patients (n = 2677), no. (%) . | de novo (n = 2310), % . | Secondary (n = 367), % . | 0-14 years (n = 340), % . | 15-34 years (n = 461), % . | 35-54 years (n = 783), % . | 55+ years (n = 1093), % . |
|---|---|---|---|---|---|---|---|
| None | 1187 (44) | 45 | 38 | 27 | 38 | 51 | 48 |
| +8 | 257 (10) | 9 | 135-150 | 14 | 10 | 7 | 105-151 |
| Complex | 241 (9) | 8 | 155-151 | 6 | 6 | 6 | 135-150 |
| t(15;17) | 241 (9) | 10 | 25-151 | 9 | 19 | 10 | 45-151 |
| −7 | 148 (6) | 4 | 125-151 | 4 | 3 | 4 | 8 |
| t(8;21) | 145 (5) | 6 | 2 | 12 | 6 | 7 | 25-151 |
| del(5q) | 108 (4) | 3 | 85-150 | 1 | 1 | 2 | 75-151 |
| −5 | 81 (3) | 3 | 55-150 | 1 | 2 | 2 | 55-151 |
| del(7q) | 80 (3) | 3 | 5 | 2 | 2 | 2 | 4 |
| 11q23 | 72 (3) | 3 | 1 | 8 | 5 | 2 | 15-151 |
| +21 | 71 (3) | 3 | 4 | 6 | 3 | 1 | 25-151 |
| inv(16) | 69 (3) | 3 | 1 | 5 | 6 | 2 | 15-151 |
| abn(3q) | 67 (3) | 2 | 45-150 | 2 | 3 | 2 | 3 |
| del(9q) | 49 (2) | 2 | 2 | 4 | 1 | 1 | 2 |
| +22 | 37 (1) | 1 | 2 | 1 | 2 | 1 | 1 |
| t(9;22) | 18 (1) | 1 | 1 | 1 | 0 | 1 | <1 |
| t(6;9) | 15 (1) | 1 | 0 | 1 | 1 | 1 | <15-151 |
| Other structural | 634 (24) | 22 | 375-151 | 29 | 18 | 20 | 275-150 |
| Other numerical | 560 (21) | 20 | 265-150 | 23 | 18 | 15 | 26 |
Percentages indicate the percentage of the column total. Percentages do not add to 100 because patients with more than one abnormality are counted more than once. P values are for Mantel-Haenszel test for trend in age (grouped) and for Fisher exact test in type of AML comparing each abnormality with normal karyotype (ie, no abnormality). P values for type of leukemia (de novo vs secondary) remain at a similar level of significance when adjusted for age group. Most P values for age group remain at a similar level of significance when adjusted for type of leukemia (de novo vs secondary) except for del(9q):P = .08 unadjusted, P < .001 adjusted; other numerical, P = .2 unadjusted, P< .001 adjusted. Secondary leukemias are more common in older patients (Mantel-Haenszel chi-square for trend, P < .001).
P < .01.
P < .001.